This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Eli Lilly Stock Up 21% in 6 Months: Time to Add to Your Portfolio?
by Kinjel Shah
Investors can buy LLY stock based on its strong overall financial performance and robust drug pipeline.
Lilly Gets FDA Approval for Eczema Drug Ebglyss
by Zacks Equity Research
The FDA approves Lilly's Ebglyss based on data from ADvocate 1, ADvocate 2 and ADhere studies.
Here's Why Biogen Inc. (BIIB) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Ionis Stock Drops 12% on Pricing of $500M Common Stock Offering
by Zacks Equity Research
IONS' shares fell after announcing the pricing of its secondary issue of shares, which were at a 12% discount to the previous closing price.
Amgen (AMGN) Up 5.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biogen's Phase II/III SMA Study for Higher Spinraza Dose Meets Goals
by Zacks Equity Research
BIIB's pivotal mid to late-stage study evaluating a higher dosing regimen for Spinraza to treat SMA in infants meets the primary and secondary goals.
Denali Plans to File for Accelerated Approval of Hunter Syndrome Drug
by Zacks Equity Research
DNLI's recent meeting with the FDA was successful and provides the path to file for accelerated approval of tividenofusp alfa for the treatment of MPS II and its subsequent conversion to full approval.
ATHA Stock Tanks as Alzheimer's Study Fails to Meet Primary Goal
by Zacks Equity Research
Athira's phase II/III LIFT-AD study on fosgonimeton for treating mild-to-moderate Alzheimer's disease fails to meet primary and secondary endpoints.
Biogen Stock Declines 20.9% Year to Date: Time to Sell?
by Kinjel Shah
BIIB's reasonable valuation, an improving pipeline and better sales prospects of new drugs are good enough reasons to stay invested for now.
Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Do Options Traders Know Something About Biogen (BIIB) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Biogen (BIIB) stock based on the movements in the options market lately.
Will Ionis' (IONS) Wholly-Owned Drugs Drive Future Growth?
by Zacks Equity Research
Ionis (IONS) enjoys a diverse revenue stream, including numerous sources of collaborative and R&D revenues. These funds enable it to invest in the development of its wholly-owned pipeline.
Is Eli Lilly (LLY) a Buy Post Stellar Q2 Earnings & Raised View?
by Kinjel Shah
Eli Lilly (LLY) is a great stock to have in one's portfolio currently based on its strong overall financial performance and robust drug pipeline.
The Zacks Analyst Blog Highlights Eli Lilly, Pfizer, AbbVie and Biogen
by Zacks Equity Research
Eli Lilly, Pfizer, AbbVie and Biogen are part of the Zacks top Analyst Blog.
3 Big Drug Stocks to Watch on Raised 2024 Earnings & Sales View
by Kinjel Shah
Here we discuss three drugmakers, Eli Lilly and Company (LLY), Pfizer (PFE) and AbbVie (ABBV), following their increase in sales and earnings guidance for 2024.
Eli Lilly (LLY) Q2 Earnings Top, Mounjaro, Zepbound Drive View
by Zacks Equity Research
Eli Lilly (LLY) beats second-quarter estimates for earnings and sales. It raises its guidance for 2024 on strong demand for Mounjaro and Zepbound.
Should You Buy, Sell or Hold Lilly (LLY) Ahead of Q2 Earnings?
by Kinjel Shah
Investor focus is likely to be on the sales numbers of Lilly's (LLY) tirzepatide medicines Mounjaro and Zepbound.
Ionis (IONS) Q2 Earnings and Revenues Beat, Stock Rises
by Zacks Equity Research
Ionis (IONS) reports better-than-expected top and bottom-line numbers for the second quarter of 2024.
Here's Why Biogen Inc. (BIIB) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Biotech Stock Roundup: BMY, GSK, BIIB's Q2 Results, VTVT Down on Setback
by Ekta Bagri
Bristol Myers (BMY) and Biogen (BIIB) are in the spotlight following earnings results and regulatory updates, respectively.
Biogen (BIIB) Q2 Earnings & Sales Beat, 2024 Guidance Raised
by Zacks Equity Research
Biogen (BIIB) beats second-quarter estimates for both earnings and sales. It raises EPS guidance and revenue growth expectations for 2024.
Sage Therapeutics (SAGE) Q2 Loss Wider Than Expected, Sales Rise
by Zacks Equity Research
Sage Therapeutics (SAGE) incurs a wider-than-expected second-quarter 2024 loss. Collaboration revenues from Zurzuvae drive year-over-year revenue growth.
Jobless Claims Tick in Higher
by Zacks Equity Research
Jobless Claims Tick in Higher.
Jobless Claims, Productivity Higher; TM, WEN, CROX Report
by Mark Vickery
Initial Jobless Claims came in at their highest levels in almost a year, to 249K -- well above the 235K anticipated.
Biogen (BIIB) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Biogen (BIIB) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.